dshah
★★  

India/United Kingdom,
2022-03-30 19:09
(729 d 21:56 ago)

(edited by dshah on 2022-03-31 11:42)
Posting: # 22889
Views: 1,923
 

 Bempedoic Acid TBM BE study in SBOA [BE/BA News]

Hello All!

I was going through SBOA of Bempedoic acid marketed as Nexleton tablets.
In general, a BE study of Phase III vs TBM formulation can suffice the need for clinical significance. But in what condition, FDA can waive such condition of BE of TBM formulation with Phase III formulations in IND filing? [image]
or considering the biopharmaceutics risk assessment- it is a low risk and study can be waived?
[image]
Regards,
Divyen Shah
jag009
★★★

NJ,
2022-03-31 10:43
(729 d 06:22 ago)

@ dshah
Posting: # 22890
Views: 1,627
 

 Bempedoic Acid TBM BE study in SBOA

Hi,
I heard from a change in the shape of the tablet will raise question as well.
J
UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,636 registered users;
114 visitors (0 registered, 114 guests [including 6 identified bots]).
Forum time: 16:05 CET (Europe/Vienna)

With four parameters I can fit an elephant,
and with five I can make him wiggle his trunk.    John von Neumann

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5